SHP465

DRUG4 trials

Sponsors

Shire

Conditions

Attention Deficit Hyperactivity Disorder (ADHD)

Phase 1

Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

CompletedNCT03327402

ShireAttention Deficit Hyperactivity Disorder (ADHD)

Start: 2018-03-13End: 2018-10-05Updated: 2021-06-08

Phase 3

Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)

CompletedNCT02466425

ShireAttention Deficit Hyperactivity Disorder (ADHD)

Start: 2015-06-18End: 2016-02-16Updated: 2021-06-03

Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years

CompletedNCT03325881

ShireAttention Deficit Hyperactivity Disorder (ADHD)

Start: 2017-12-09End: 2018-06-07Updated: 2021-06-02

Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)

TerminatedNCT03325894

ShireAttention Deficit Hyperactivity Disorder (ADHD)

Start: 2018-01-02End: 2019-01-19Updated: 2021-06-03

Related Papers

Pharmacokinetics, Safety, and Tolerability of SHP465 Mixed Amphetamine Salts After Administration of Multiple Daily Doses in Children Aged 4-5 Years with Attention-Deficit/Hyperactivity Disorder.

2021-11-263 citations

A Phase 3, Randomized Double-Blind Study of the Efficacy and Safety of Low-Dose SHP465 Mixed Amphetamine Salts Extended-Release in Children with Attention-Deficit/Hyperactivity Disorder

Journal of Child and Adolescent Psychopharmacology2020-10-145 citations